Breast cancer humoral immune response: Involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1)

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Larrain, Marina Isla ^a   Demichelis, Sandra ^a   Crespo, Marina ^a   Lacunza, Ezequiel ^a   Barbera, Alberto ^b   Cretán, Aldo ^b   Terrier, Francisco ^b   Segal Eiras, Amada ^a   Croce, María Virginia ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^b Breast Foundation   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CARBOHYDRATE; LEWIS Y ANTIGEN; LEWIS Y MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MUCIN 1; MUCIN 1 MONOCLONAL ANTIBODY; OLIGOSACCHARIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BENIGN TUMOR; BLOOD SAMPLING; BREAST CANCER; CLINICAL EVALUATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; WESTERN BLOTTING; BLOOD; BLOOD GROUP LEWIS SYSTEM; BREAST TUMOR; CANCER STAGING; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGEN-ANTIBODY COMPLEX; BLOTTING, WESTERN; BREAST NEOPLASMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LEWIS BLOOD-GROUP SYSTEM; MIDDLE AGED; MUCIN-1; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 79959339930     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-121     Document Type: Article

References (44)

1. High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Z Madjd T Parsons NF Watson I Spendlove I Ellis LG Durrant, Breast Cancer Res 2005 7 780 787 10.1186/bcr1305
2. Biochemical basis and clinical application of tumor-associated carbohydrate antigens: current trends and future perspectives. S Hakomori, Gan To Kagaku Ryoho 1989 16 715 731 Review. 2468313
3. A family of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-transferases control the initiation of mucin-type O-linked glycosylation. H Clausen EP Bennett, Glycobiology 1996 6 635 646 10.1093/glycob/6.6.635 8922959
4. O-linked glycosylation in the mammary gland: changes that occur during malignancy. JM Burchell A Mungul J Taylor-Papadimitriou, J Mammary Gland Biol Neoplasia 2001 6 355 364 Review. 10.1023/A:1011331809881 11547903
5. Activation-dependent expression of the blood group-related Lewis y antigen on peripheral blood granulocytes. M Dettke G Plfi H Loibner, J Leukoc Biol 2000 68 511 514 11037972
6. Quantitative dot blot analyses of blood-group-related antigens in paired normal and malignant human breast tissues. Y Ura AS Dion CJ Williams BD Olsen ES Redfield M Ishida M Herlyn PP Major, Int J Cancer 1992 50 57 63 10.1002/ijc.2910500113 1728614
7. Complexity of expression of antigenic determinants recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells. JM Burchell H Durbin J Taylor-Papadimitriou, J Immunol 1983 131 508 513 6190927
8. Demonstration by monoclonal antibodies that carbohydrate strctures of glycoproteins and glycolipids are onco-developmental antigens. T Feizi, Nature 1985 314 53 57 10.1038/314053a0 2579340
9. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. J Wesseling SW van der Valk J Hilkens, Mol Biol Cell 1996 7 565 577 8730100
10. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. S von Mensdorff-Pouilly AA Verstraeten P Kenemans FG Snijdewint A Kok GJ Van Kamp MA Paul PJ Van Diest S Meijer J Hilgers, J Clin Oncol 2000 18 574 583 10653872
11. Augmenting the immunogenicity of carbohydrate antigens. PO Livingston, Cancer Vaccines Sem Cancer Biol 1995 6 357 366 10.1016/1044-579X(95)90005-5
12. The case for polyvalent cancer vaccines that induce antibodies. G Ragupathi P Livingston, Expert Rev Vaccines 2002 1 193 206 Review. 10.1586/14760584.1.2.193 12901558
13. Immune complexes in human malignant tumours. A review. A Segal-Eiras MV Croce, Allergol Immunopathol 1984 12 225 232
14. Presence of fucolipid antigens with mono- and dimeric X determinant (Lex) in the circulating immune complexes of patients with adenocarcinoma. AK Singhal MC Singhal E Nudelman S Hakomori JP Balint CK Grant HW Snyder Jr, Cancer Res 1987 47 5566 5571 2444333
15. Humoral immune response to polymorphic epithelial mucin (MUC1) in patients with benign and malignant breast tumours. S von Mensdorff-Pouilly MM Gourevitch P Kenemans AA Verstraeten SV Litvinov GJ van Kamp S Meijer J Vermorken J Hilgers, Eur J Cancer 1996 32 1325 1331 10.1016/0959-8049(96)00048-2 (Pubitemid 26246705)
16. Tissue and serum MUC1 mucin detection in breast cancer patients. MV Croce MT Isla Larrain SO Demichelis JR Gori MR Price A Segal-Eiras, Breast Cancer Res Treat 2003 81 195 207 10.1023/A:1026110417294 14620915
17. Polymorphic epithelial mucin (MUC1)-containing circulating immune complexes in carcinoma patients. MM Gourevitch S von Mensdorff-Pouilly SV Litvinov P Kenemans GJ van Kamp AA Verstraeten J Hilgers, Br J Cancer 1995 72 934 938 7547243
18. Immunological approaches to tumor therapy. Monoclonal antibodies, tumor vaccines and anti-idiotypes. KE Hellström I Hellström, Targeted Diagn Ther 1989 2 1 39 Review. 2519542
19. Clinical relevance of immune complexes, associated antigen, and antibody in cancer. FA Salinas KH Wee HK Silver, Contemp Top Immunobiol 1985 15 55 109 Review. 3896644
20. Targeting of iodine-123-labelled tumor-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumors. AA Epenetos KE Britton S Mather J Shepherd M Granowska J Taylor-Papadimitriou CC Nimmon H Durbin LR Hawkins JS Malpas WF Bodmer, Lancet 1982 2 999 1005 10.1016/S0140-6736(82)90046-0 6127540
21. Immunohistochemical localization of Y hapten and the structurally related H type-2 blood-group antigen on large-bowel tumors and normal adult tissues. A Brown IO Ellis MJ Embleton RW Baldwin DR Turner JD Hardcastle, Int J Cancer 1984 33 727 736 10.1002/ijc.2910330604 6203846
22. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. UK Laemmli, Nature 1970 227 680 685 10.1038/227680a0 5432063
23. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. H Towbin T Staehelin J Gordon, Proc Natl Acad Sci USA 1979 76 4350 4354 10.1073/pnas.76.9.4350 388439
24. Lewis x is highly expressed in normal tissues: a comparative immunohistochemical study and literature revision. MV Croce M Isla Larrain ME Rabassa S Demichelis AG Colussi M Crespo E Lacunza A Segal-Eiras, Pathol Oncol Res 2007 13 130 138 Review. 10.1007/BF02893488 17607374
25. Carbohydrate determinants associated with carcinoembryonic antigen (CEA). EJ Nichols R Kannagi SI Hakomori MJ Krantz A Fuks, J Immunol 1985 135 1911 1913 2410505
26. Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. B Fernandes U Sagman M Auger M Demetrio JW Dennis, Cancer Res 1991 51 718 723 1985789
27. Correlation between the sialylation of cell surface Thomsen-Friedenreich antigen and the metastatic potential of colon carcinoma cells in a mouse model. Y Nemoto-Sasaki M Mitsuki M Morimoto-Tomita A Maeda M Tsuiji T Irimura, Glycoconj J 2001 18 895 906 10.1023/A:1022252509765 12820723
28. Distinct sub-populations of carcinoma-associated MUC1 mucins as detected by the monoclonal antibody 9H8 and antibodies against the sialyl-Lewis a and sialyl-Lewis x epitopes in the circulation of breast-cancer patients. R Sikut K Zhang D Baeckström GC Hansson, Int J Cancer 1996 66 617 623 10.1002/(SICI)1097-0215(19960529)66:5<617::AID-IJC63.0.CO;2-W 8647622
29. Presence of tumor-associated antigens in epidermal growth factors receptors from different human carcinomas. A Basu U Murthy U Rodeck M Herlyn L Mattes M Das, Cancer Res 1987 47 2531 2536 2436750
30. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. I Hellström HJ Garrigues U Garrigues KE Hellström, Cancer Res 1990 50 2183 2190 1690595
31. Glycosylation alterations of cells in late phase apoptosis from colon carcinomas. E Rapoport J Le Pendu, Glycobiology 1999 9 1337 1345 10.1093/glycob/9.12.1337 10561459
32. Expression of cell surface Lewis x and y antigens and FUT4 mRNA is increased in Jurkat cells undergoing apoptosis. Y Azuma M Ito A Taniguchi K Matsumoto, Biochim Biophys Acta 2004 1672 157 163 15182935
33. Increased expression of the blood group-related Lewis Y antigen on synovial fluid granulocytes of patients with arthritic joint diseases. M Dettke G Plfi E Pursch MV Fisher H Loibner, Rheumatology 2001 40 1033 1037 10.1093/rheumatology/40.9.1033 11561115
34. A specific cell surface glycoconjugate controlling cell motility: Evidence by functional antibodies that inhibit cell motility and tumor cell metastasis. M Miyake SI Hakomori, Biochemistry 1991 30 3328 3334 10.1021/bi00227a023 2009271
35. Expression of tumor associated antigens in normal, benign and malignant human mammary epithelial tissue: a comparative immunohistochemical study. MV Croce AG Colussi MR Price A Segal-Eiras, Anticancer Res 1997 17 4287 4292 9494522
36. Antibodies directed against Lewis y antigen inhibit signaling of Lewis-Y modified ErbB receptors. M Klinger H Farhan H Just H Drobny G Himmler H Loibner GC Mudde M Freissmuth V Sexl, Cancer Res 2004 64 1087 1093 10.1158/0008-5472. CAN-03-2435 14871842
37. Ley/H: an endothelial-selective, cytokine-inducible, angiogenic mediator. MM Halloran WW Carley PJ Polverini CJ Haskell S Phan BJ Anderson JM Woods PL Campbell MV Volin AE Bäcker AE Koch, J Immunol 2000 164 4868 4877 10779796
38. Does vimentin help to delineate the so-called 'basal type breast cancer'? R Kusinska R Kordek E Pluciennik AK Bednarek JHi Piekarsk P Potemski, Journal of Experimental & Clinical Cancer Research 2009 28 118 10.1186/1756-9966-28- 118
39. MUC1 glycoforms in breast cancer-cell line T47D as a model for carcinoma-associated alterations of 0-glycosylation. FG Hanisch TR Stadie F Deutzmann J Peter-Katalinic, Eur J Biochem 1996 236 318 327 10.1111/j.1432-1033. 1996.00318.x 8617281
40. Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis y conjugates in mice. V Kudryashov PW Glunz LJ Williams S Hintermann SJ Danishefsky KO Lloyd, Proc Natl Acad Sci USA 2001 98 3264 3269 11248067 10.1073/pnas.051623598 (Pubitemid 32220834)
41. Cancer vaccines targeting carbohydrate antigens. PO Livingston G Ragupathi, Hum Vaccin 2006 2 137 143 17012906
42. Reactivity of natural and induced humoral antibodies to MUC1 mucin with MUC1 peptides and n-actylgalactosamine (GalNAc) peptides. S von Mensdorff-Pouilly E Petrakou P Kenemans K van Uffelen AA Verstraeten FG Snjdewint GJ van Kamp DJ Schol CA Reis MR Price PO Livingston J Hilgers, Int J Cancer 2000 86 703 712 10.1002/(SICI)1097-0215(20000601)86:5<702::AID-IJC163. 0.CO;2-1
43. Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. AW Silk RE Schoen DM Potter OJ Finn, Mol Immunol 2009 19217667
44. Cancer immunology. OJ Finn, N Engl J Med 2008 358 2704 2715 Review. 10.1056/NEJMra072739 18565863